J.P. Morgan Keeps Their Hold Rating on Pfizer (PFE)
J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer with a $30 price target. Bank of America also issued a Hold, while Jefferies kept a Buy rating. Pfizer reported Q2 revenue of $15.03B and a net loss of $246M, down from last year's $2.91B profit. Insider sentiment is positive, with recent buying activity.
How this was made
The 30-second read
Why it matters
The Hold rating with a $30 target may cause modest price adjustments, especially if current price deviates from the target.
Market read
Provides a fresh analyst viewpoint that could modestly influence Pfizer's share price and sector sentiment.
What to watch
Potential upcoming FDA decisions or pipeline milestones not covered in the article could shift sentiment.
Background
Analyst rating updates are routine but can move the stock if the target differs from market expectations.
Ticker impact
J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer and set a price target of $30.00.
neutral to slight downside as the target may be below current market price
Analyst rating is new but modest; no major catalyst beyond the target, so market reaction is expected to be muted.
Market effects
The rating may influence sentiment across the broader healthcare sector as peers are often compared to Pfizer.
Limited regional impact; primarily relevant to U.S. investors.
Minimal global effect beyond large-cap pharma exposure.
Counterpoint
Some investors may view the Hold as a buying opportunity if they believe the $30 target undervalues Pfizer's pipeline.
Key entities
- Financial InstitutionJ.P. Morgan
Equity research firm providing the rating.
- CompanyPfizer
US-listed pharmaceutical company (ticker PFE).